PMID- 33084958 OWN - NLM STAT- MEDLINE DCOM- 20210714 LR - 20231017 IS - 1436-6215 (Electronic) IS - 1436-6207 (Linking) VI - 60 IP - 5 DP - 2021 Aug TI - Long-term effects of increasing omega-3, omega-6 and total polyunsaturated fats on inflammatory bowel disease and markers of inflammation: a systematic review and meta-analysis of randomized controlled trials. PG - 2293-2316 LID - 10.1007/s00394-020-02413-y [doi] AB - BACKGROUND AND AIM: Effects of long-chain omega-3 (LCn3) and omega-6 fatty acids on prevention and treatment of inflammatory bowel diseases (IBD, including Crohn's Disease, CD and ulcerative colitis, UC), and inflammation are unclear. We systematically reviewed long-term effects of omega-3, omega-6 and total polyunsaturated fats (PUFA) on IBD diagnosis, relapse, severity, pharmacotherapy, quality of life and key inflammatory markers. METHODS: We searched Medline, Embase, Cochrane CENTRAL, and trials registries, including RCTs in adults with or without IBD comparing higher with lower omega-3, omega-6 and/or total PUFA intake for >/= 24 weeks that assessed IBD-specific outcomes or inflammatory biomarkers. RESULTS: We included 83 RCTs (41,751 participants), of which 13 recruited participants with IBD. Increasing LCn3 may reduce risk of IBD relapse (RR 0.85, 95% CI 0.72-1.01) and IBD worsening (RR 0.85, 95% CI 0.71-1.03), and reduce erythrocyte sedimentation rate (ESR, SMD - 0.23, 95% CI - 0.44 to - 0.01), but may increase IBD diagnosis risk (RR 1.10, 95% CI 0.63-1.92), and faecal calprotectin, a specific inflammatory marker for IBD (MD 16.1 mug/g, 95% CI - 37.6 to 69.8, all low-quality evidence). Outcomes for alpha-linolenic acid, omega-6 and total PUFA were sparse, but suggested little or no effect where data were available. CONCLUSION: This is the most comprehensive meta-analysis of RCTs investigating long-term effects of omega-3, omega-6 and total PUFA on IBD and inflammatory markers. Our findings suggest that supplementation with PUFAs has little or no effect on prevention or treatment of IBD and provides little support for modification of long-term inflammatory status. CI - (c) 2020. Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Ajabnoor, Sarah M AU - Ajabnoor SM AUID- ORCID: 0000-0003-0996-1484 AD - Norwich Medical School, University of East Anglia, Norwich, UK. smajabnoor@kau.edu.sa. AD - Clinical Nutrition Department, Faculty of Applied Medical Sciences, King Abdulaziz University, P.O. Box 80324, Jeddah, 21589, Saudi Arabia. smajabnoor@kau.edu.sa. FAU - Thorpe, Gabrielle AU - Thorpe G AUID- ORCID: 0000-0002-0639-4229 AD - School of Health Sciences, University of East Anglia, Norwich, UK. FAU - Abdelhamid, Asmaa AU - Abdelhamid A AUID- ORCID: 0000-0002-9897-5433 AD - Norwich Medical School, University of East Anglia, Norwich, UK. FAU - Hooper, Lee AU - Hooper L AUID- ORCID: 0000-0002-7904-3331 AD - Norwich Medical School, University of East Anglia, Norwich, UK. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review PT - Systematic Review DEP - 20201021 PL - Germany TA - Eur J Nutr JT - European journal of nutrition JID - 100888704 RN - 0 (Biomarkers) RN - 0 (Fatty Acids, Omega-3) SB - IM MH - Adult MH - Biomarkers MH - *Fatty Acids, Omega-3 MH - Humans MH - Inflammation MH - *Inflammatory Bowel Diseases MH - Quality of Life MH - Randomized Controlled Trials as Topic OTO - NOTNLM OT - Alpha-linolenic acid OT - C-reactive protein OT - Dietary fats, unsaturated OT - Fatty acids, omega-3 OT - Fatty acids, omega-6 OT - Inflammatory bowel diseases OT - Meta-analysis EDAT- 2020/10/22 06:00 MHDA- 2021/07/15 06:00 CRDT- 2020/10/21 12:25 PHST- 2020/03/06 00:00 [received] PHST- 2020/10/06 00:00 [accepted] PHST- 2020/10/22 06:00 [pubmed] PHST- 2021/07/15 06:00 [medline] PHST- 2020/10/21 12:25 [entrez] AID - 10.1007/s00394-020-02413-y [pii] AID - 10.1007/s00394-020-02413-y [doi] PST - ppublish SO - Eur J Nutr. 2021 Aug;60(5):2293-2316. doi: 10.1007/s00394-020-02413-y. Epub 2020 Oct 21.